These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21878454)

  • 1. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
    Notcutt W; Langford R; Davies P; Ratcliffe S; Potts R
    Mult Scler; 2012 Feb; 18(2):219-28. PubMed ID: 21878454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
    Novotna A; Mares J; Ratcliffe S; Novakova I; Vachova M; Zapletalova O; Gasperini C; Pozzilli C; Cefaro L; Comi G; Rossi P; Ambler Z; Stelmasiak Z; Erdmann A; Montalban X; Klimek A; Davies P;
    Eur J Neurol; 2011 Sep; 18(9):1122-31. PubMed ID: 21362108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
    Collin C; Ehler E; Waberzinek G; Alsindi Z; Davies P; Powell K; Notcutt W; O'Leary C; Ratcliffe S; Nováková I; Zapletalova O; Piková J; Ambler Z
    Neurol Res; 2010 Jun; 32(5):451-9. PubMed ID: 20307378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.
    Wade DT; Collin C; Stott C; Duncombe P
    Mult Scler; 2010 Jun; 16(6):707-14. PubMed ID: 20558502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
    Leocani L; Nuara A; Houdayer E; Schiavetti I; Del Carro U; Amadio S; Straffi L; Rossi P; Martinelli V; Vila C; Sormani MP; Comi G
    J Neurol; 2015 Nov; 262(11):2520-7. PubMed ID: 26289497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C; Davies P; Mutiboko IK; Ratcliffe S;
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
    J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.
    Kavia RB; De Ridder D; Constantinescu CS; Stott CG; Fowler CJ
    Mult Scler; 2010 Nov; 16(11):1349-59. PubMed ID: 20829244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
    Oreja-Guevara C
    Expert Rev Neurother; 2012 Apr; 12(4 Suppl):3-8. PubMed ID: 22509985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
    Sastre-Garriga J; Vila C; Clissold S; Montalban X
    Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
    Meuth SG; Vila C; Dechant KL
    Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?
    Wade D
    Expert Rev Neurother; 2012 Apr; 12(4 Suppl):9-14. PubMed ID: 22509986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
    Serpell MG; Notcutt W; Collin C
    J Neurol; 2013 Jan; 260(1):285-95. PubMed ID: 22878432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
    Flachenecker P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
    Arroyo R; Vila C; Dechant KL
    J Comp Eff Res; 2014 Jul; 3(4):435-44. PubMed ID: 25275238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
    Slof J; Gras A
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):439-41. PubMed ID: 22681512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.